FTC/DoJ Revision Of Merger Guidelines Unlikely To Alter Pharma Deals

The Federal Trade Commission and Department of Justice are revising their guidelines for evaluating whether horizontal mergers are anticompetitive. While they may decide to consider additional factors in their analysis, antitrust lawyers do not expect to see a major change for drug firms